Diligence memo · auto-generated · as of July 2, 2026
Pure Bioscience, Inc.
Pure Bioscience, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Pure Bioscience, Inc. operates in Biotech, based in EL CAJON.
Sub-sector tags: biotech.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Pure Bioscience, Inc. has raised $29M in disclosed capital across 13 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $9.9M on 2014-08-22.
Most recent recorded round closed around 2017-01-23.
Valuation (modeled)modeled
Provath models Pure Bioscience, Inc. at approximately $12M (range $368K–$66M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.05× the median modeled value of Series A Biotech companies in 2016–2018 (8 peers) — value vs value, same stage and era. Issuer reports $1M–$5M revenue while modeled below niche peers.
Financing rhythm & timingmixed
Historic cadence: a new round about every 6 months.
Last raise 9.4 yr ago; this sector typically re-raises about every 11 months.
Silent for over 3× the sector's normal cadence.
The last round was 3.0× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 93% of Biotech peers (233 compared).
Modeled value ranks above 75% of those peers.
Closest niche peers: Montlake Bioscience Inc., Impact Genomics, Inc., Transplant Genomics Inc., Benchling, Inc., Franklin BioScience - Penn LLC.
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.